Enliven Therapeutics, Inc.

    Jurisdiction
    United States
    ISIN
    US29337E1029 (ELVN)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€98.07M
    EBIT margin
    0.0%
    Net income
    -€86.03M
    Net margin
    0.0%

    Statement period: - (published )

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Hohl Benjamin CHIEF FINANCIAL OFFICER -3.3K $20.63 -$67.05K
    Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER -13K $19.86 -$248.25K
    Kintz Samuel PRESIDENT AND CEO -11K $20.02 -$219.88K
    Patel Anish CHIEF OPERATING OFFICER -6.7K $18.24 -$121.61K
    Hohl Benjamin CHIEF FINANCIAL OFFICER -3.3K $20.46 -$66.50K

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 12K $234.19K -24K Sell

    Add to watchlist

    Notifications